Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
AGC Biologics said it is laying off a total of 95 staffers, which will be effective from November. The manufacturing company is cutting 80 workers in Colorado, 63 of whom are in Longmont and 17 are in Boulder. Another 10 staffers will be cut in Bothell, WA. The company’s Longmont factory will remain “partially open,” according to a WARN notice published last week.
Lonza has become the third publicly announced manufacturer to make Vertex Pharmaceuticals’ Casgevy, according to a Tuesday release. Lonza will make commercial Casgevy at its facility in Geleen, the Netherlands, with plans to also make it in Portsmouth, NH, in 2025. RoslinCT and Charles River Laboratories are the other two companies previously tapped by Vertex to make the gene therapy.
Eurofins CDMO Alphora is building a new 50,000 square foot facility to manufacture monoclonal antibodies and protein-based therapies, the company said Tuesday. The new site at Eurofins’ Sheridan Research Park campus in Ontario will open in April 2026. The Canadian government has contributed $64.1 million to help Eurofins build the factory.
Bavarian Nordic has secured $63 million from the Biomedical Advanced Research and Development Authority to manufacture its smallpox and mpox vaccine Jynneos. The vaccines will be manufactured next year for rollout in 2026, according to a Tuesday announcement.
Thermo Fisher Scientific is expanding its factories in Cincinnati, OH, and Bend, OR, to boost its oral solid dose manufacturing capacity. The facility in Bend will double its footprint and house R&D manufacturing and testing for oral solid doses, the company said Thursday.
Legend Biotech will evaluate Multiply Labs’ robotic technology in its potential to manufacture cell therapies, the companies announced Tuesday.
Capricor Therapeutics has established internal commercial manufacturing for its Duchenne muscular dystrophy cardiomyopathy asset named deramiocel. The company is planning to submit a biologics license application to the FDA in October, the company said Tuesday.
Private equity firm Blue Wolf Capital Partners has completed its acquisition of seven manufacturing facilities in Europe from the CDMO Recipharm, according to a Wednesday release. The acquisition was first announced in April.
Ophthalmic pharma company Harrow is expanding its headquarters in Nashville and will hire an additional 150 people, the company said Wednesday.
Lonza has extended its collaboration with Acumen Pharmaceuticals to manufacture the Phase 2 asset sabirnetug, which is being investigated for Alzheimer’s disease, the companies said Thursday. Acumen originally tapped Lonza to make sabirnetug in April.
CDMO SK pharmteco and supply chain logistics company Cryoport announced a new partnership Wednesday. Cryoport will handle SK pharmteco’s supply chains for small molecules and cell and gene therapies, including shipping and collecting materials.